Precision BioSciences, Inc. announced its financial results for Q4 and FY 2025, highlighting a significant revenue increase to $34.2 million from $0.6 million in Q4 2024. The company also reported a net income of $20.1 million, showcasing strong operational execution and a positive outlook for ongoing clinical trials.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.